Everyone is keeping a very close eye on the spread of the Coronavirus symptoms. Mild panic has occurred with many providers selling out of face masks as people aim to protect themselves. Amidst the chaos, a Texas based pharmaceutical company is looking to make the most out of this and boost some sales of their cannabis extract.
Kali-Extracts Inc. is claiming that their product RespRX, a CBD formulation, could potentially treat the symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other respiratory-related health conditions. This would then extend into the sphere of the Coronavirus and the symptoms it exhibits.
When asked for further comment, the company seemed hesitant. On their website though, they have said that this formula is years in the making, using a CBD formulation from an extraction process featured in the Journal of Cannabis Research. The research says that cannabis oil extracts have been seen to alleviate COPD symptoms thanks to the anti-inflammatory properties of cannabis.
A statement from Kali-Extracts reads that “In conjunction with the research already conducted and the next phase of research now moving forward, the company has filed a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions,”
The company has made some bold claims, which is why not everyone is in agreement. Medical director at a Canadian based data company, Dr Paola Cubillos, was quoted saying “Holy!!! This is going too far.”. Medical Genomics founder, Kevin McKernan, tweeted: “Bummer. There is actually some exciting preliminary work on cannabinoids and viruses that are now getting sold before it’s (…) understood.”.
As noted in the study, the research and relevant findings are still in the early stages. What we have seen thus far is a push to research further and explore the possibilities. However, it is bold of a company to make any sorts of claims, just in general. But particularly in the case of a virus that is running rampant at the moment.